CAMBRIDGE, Mass. (May 22, 2012) – Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.
A new clinical trial for breast cancer, published in The Lancet, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM® at time of lumpectomy is non-inferior to traditional ... Read Post
A clinical trial involving collaboration between researchers at Whitehead Institute and Dana Farber Cancer Institute is now enrolling patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer. The trial wi... Read Post